
Jonathan Chatzkel, MD, discusses the rationale for the phase Ib/II IMMCO-1 trial investigating the combination of atezolizumab plus tivozanib in metastatic castration-resistant prostate cancer and other immunologically cold tumors.

Jonathan Chatzkel, MD, discusses the rationale for the phase Ib/II IMMCO-1 trial investigating the combination of atezolizumab plus tivozanib in metastatic castration-resistant prostate cancer and other immunologically cold tumors.

Jonathan A. Chatzkel, MD, discusses the future treatment options in bladder cancer.

Jonathan A. Chatzkel, MD, discusses the emergence of novel therapies in relapsed/refractory locally advanced or metastatic urothelial cancer.

February 17th 2022